Cambridge ICU gets pneumonia results within hours

beehiveweb.co.uk editorial team 2026-08-03 16:52 3 min read

Automated laboratory equipment analyzing blood samples in a modern clinical diagnostic testing facility.

By the Beehive Web Health Desk | 3 August 2026

Critically ill patients at Addenbrooke’s Hospital can now be tested for pneumonia using a system that produces results in hours rather than the several days required by traditional microbiological assays.

Cambridge University Hospitals reported on 3 August that its Ventilator Acquired Pneumonia test had entered clinical practice in the John Farman Intensive Care Unit. Clinicians will use the findings to help select treatments while caring for patients with suspected infections.

A decade-long project reaches intensive-care practice

The clinical deployment follows more than a decade of development led by ICU consultants Dr Vilas Navapurkar and Dr Andrew Conway Morris, who also works in the University of Cambridge’s Department of Medicine.

Cambridge-based diagnostics company EDX Medical helped complete the test’s development and technical validation alongside Thermo Fisher Scientific. Earlier work involved the UK Health Security Agency, and the test was used during the Covid period.

EDX Medical licensed the test’s intellectual property and clinical research data from Cambridge University Hospitals and the UK Health Security Agency in 2025 through Cambridge Enterprise.

Its arrival in the ICU is a clinical milestone, but it is not yet a national rollout. The hospital’s announcement does not provide patient numbers, detailed performance measurements or an exact average turnaround time beyond saying that results can be produced in hours.

Cambridge ICU gets pneumonia results within hours

Lung-fluid samples are analysed on a diagnostic card

The test examines fluid collected from the lungs. A sample is placed into recesses on a plastic card, which is then inserted into a dedicated machine for analysis.

It is designed to detect or exclude a range of bacterial, viral and fungal pathogens. That breadth matters in intensive care because pneumonia can have different causes, while the appropriate treatment depends on what is driving the infection.

The Cambridge clinicians have also published research identifying three pneumonia subtypes that may require different treatment approaches. The new test gives the ICU team faster information to support those decisions, although the source does not claim that it replaces every existing laboratory investigation.

Faster evidence can sharpen treatment decisions

Receiving results within hours may allow clinicians to identify suitable drugs, doses and treatment durations earlier. It may also show when particular pathogens are absent, giving the medical team evidence to reassess treatment.

Dr Navapurkar said the test had already shown a beneficial impact for patients in the Addenbrooke’s ICU. The announcement does not quantify that impact or report comparative patient outcomes, so its wider clinical effect will depend on evidence gathered during routine use.

The system can also test community-acquired pneumonia, although its current deployment described by the hospital is focused on critically ill patients in the John Farman Intensive Care Unit.

Targeted prescribing supports antimicrobial stewardship

Quicker identification or exclusion of pathogens can help clinicians avoid using an unsuitable drug or continuing treatment longer than necessary. Cambridge University Hospitals says this should reduce side effects and limit the conditions in which drug resistance can develop.

The potential resource implications are substantial. According to figures cited by the hospital, hospital-acquired pneumonia costs the NHS an estimated £1.5 billion annually and accounts for almost one million bed days. Community-acquired pneumonia is estimated to cost a further £731 million.

Those figures describe the scale of pneumonia-related pressure on the health service; the announcement does not estimate how much money or bed capacity this test will save.

Real-world data will determine the next stage

EDX Medical chief executive Dr Mike Hudson said the company is now collecting real-world data for regulators. That evidence is intended to support regulatory approval and make the test more widely available.

Dr Navapurkar said the Cambridge team would continue supporting the partnership with EDX Medical as it works towards wider use in intensive-care units across the UK and Europe. Until that process is completed, the confirmed deployment remains the John Farman Intensive Care Unit at Addenbrooke’s Hospital.

Source: Cambridge University Hospitals News

Context & actions About this article

Source check Source trail

The deployment, testing process, development history and stated next steps were checked against Cambridge University Hospitals' report dated 3 August 2026.

Checks

Confirmed that the test has entered clinical practice in the John Farman Intensive Care Un...
Preserved the source's comparison of results in hours with several days for traditional as...
Checked the named development partners and the 2025 intellectual-property licensing timeli...
Presented NHS cost and bed-day figures as estimates cited by the hospital.

Cambridge University Hospitals News Check wider reporting